Abstract:Gastrointestinal cancer has a high incidence in China, especially upper gastrointestinal cancer (esophageal and gastric cancer). Although the incidence has been declining in recent years, the annual incidence of new cases accounts for more than 50% of global cases, and the incidence of colorectal cancer in big cities like Beijing and Shanghai is increasing annually but the mortality rate has not yet increased significantly. Gradual implementation and promotion of multidisciplinary team (MDT) reduced the mortality of gastrointestinal tumors, but this change is not obvious. Successful clinical studies of immune checkpoint inhibitors [programmed death-1 (PD-1), programmed death ligand 1 (PD-L1)] for esophageal and gastric cancer have changed clinical treatment strategies. The overall survival of advanced patients has improved but the comprehensive treatment of locally advanced patients warrants further research. In addition to the microsatellite instability high (MSI-H) population, few drugs have changed the clinical outcome of colorectal cancer in the past decade, which makes it difficult to affect the prognosis of patients. Clinical research on MDT is difficult to conduct, resulting in less data accumulation in this field. The heterogeneity of gastrointestinal tumors is relatively strong and precise treatment should be the direction of future development. In this regard, several studies have been conducted and developed rapidly in recent years in China, including those on MSI-H, human epidermal growth factor receptor 2 (HER2), c-mesenchymal-epithelial transition factor (c-MET), B-Raf proto-oncogene serine/threonine kinase (BRAF), rat sarcoma virus (RAS), fibroblast growth factor receptors (FGFR) and polymerases epsilon (POLE). The selection of immunotherapy markers, as well as the discovery of efficacy and prognostic markers, are also clinicians' concerns. Several articles presented in this issue reflect the research carried out by Chinese researchers based on clinical problems. These concerns of clinicians would impact the clinical practice. However, due to the limitation of time and level, the findings cannot fully reflect the current level of gastrointestinal cancer research in China which is expected to develop rapidly in the future.

Gastrointestinal Cancer Research in the Era of Precision Medicine

Current Status and Challenges of Gastrointestinal Cancer Treatment in China

Plenary Paper

Esophageal Cancer in High-Risk Areas of China: Research Progress and Challenges

[New Perspectives on Medical Treatment of Gastric Cancer].

Research Status and Progress on Treatment of Advanced Gastric Cancer

Advances in Targeted Treatment for Gastric Cancer

Predicting Peritoneal Dissemination Of Gastric Cancer In The Era Of Precision Medicine: Molecular Characterization And Biomarkers

Update and progress of comprehensive treatment for advanced gastric cancer

Recent Advances in the Diagnosis, Staging, Treatment, and Prognosis of Advanced Gastric Cancer: A Literature Review

Application of Molecular Targeted Agents in Comprehensive Treatment of Gastrointestinal Cancer

Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers

Towards personalized perioperative treatment for advanced gastric cancer.

Progress in Clinical Research of Gastric Cancer

Research Frontiers in Precision Therapy for Liver Cancer

Progress of Gastric Cancer Surgery in the era of Precision Medicine

The landscape of cancer research and cancer care in China

Translational research and application of basic biology to clinical trial development in GI cancers

Cancer Statistics: Current Diagnosis and Treatment of Pancreatic Cancer in Shanghai, China.

Cancer Prevention Research in China

Dissecting gastric cancer heterogeneity and exploring therapeutic strategies using bulk and single-cell transcriptomic analysis and experimental validation of tumor microenvironment and metabolic interplay